Lasmiditan succinate - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What are the generic sources for lasmiditan succinate and what is the scope of freedom to operate?

Lasmiditan succinate is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lasmiditan succinate has eighty-one patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for lasmiditan succinate

International Patents:	81
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	14
Patent Applications:	1
DailyMed Link:	lasmiditan succinate at DailyMed

US Patents and Regulatory Information for lasmiditan succinate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-002	Jan 31, 2020		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020		DISCN	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-003	Dec 18, 2020		DISCN	Yes	No	See Plans and Pricing	See Plans and Pricing	Y	Y		See Plans and Pricing
Eli Lilly And Co	REYVOW	lasmiditan succinate	TABLET;ORAL	211280-001	Jan 31, 2020		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for lasmiditan succinate

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
South Africa	201903449	COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS	See Plans and Pricing
Israel	266598	תכשירים ושיטות הקשורים לאגוניסטים של פירידינוילפיפרידין 5-ht1f (Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists)	See Plans and Pricing
China	1642939	Pyridinoylpiperidines as 5-HTLF agonists	See Plans and Pricing
Australia	2003224719	PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS	See Plans and Pricing
Tunisia	2019000174	COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS	See Plans and Pricing
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.